The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $14.17 down -2.68% from its previous closing price of $14.56. In other words, the price has decreased by -$2.68 from its previous closing price. On the day, 3.35 million shares were traded. OCUL stock price reached its highest trading level at $14.8532 during the session, while it also had its lowest trading level at $14.14.
Ratios:
For a deeper understanding of Ocular Therapeutix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.78 and its Current Ratio is at 7.85. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In the most recent recommendation for this company, Chardan Capital Markets on September 15, 2025, initiated with a Buy rating and assigned the stock a target price of $21.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.RBC Capital Mkts initiated its Outperform rating on March 18, 2025, with a $17 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 24 ’25 when Nayak Sanjay sold 1,878 shares for $12.04 per share. The transaction valued at 22,611 led to the insider holds 277,860 shares of the business.
Dugel Pravin sold 19,530 shares of OCUL for $235,141 on Nov 24 ’25. The insider now owns 3,157,960 shares after completing the transaction at $12.04 per share. On Nov 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,007 shares for $12.02 each. As a result, the insider received 36,144 and left with 191,433 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 3018882816 and an Enterprise Value of 2751118592. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.12 while its Price-to-Book (P/B) ratio in mrq is 9.60. Its current Enterprise Value per Revenue stands at 49.318 whereas that against EBITDA is -10.585.
Stock Price History:
The Beta on a monthly basis for OCUL is 0.90, which has changed by 0.6141907 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $16.44, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is 17.57%, while the 200-Day Moving Average is calculated to be 38.60%.
Shares Statistics:
For the past three months, OCUL has traded an average of 3.17M shares per day and 4737100 over the past ten days. A total of 213.05M shares are outstanding, with a floating share count of 186.91M. Insiders hold about 12.27% of the company’s shares, while institutions hold 79.00% stake in the company. Shares short for OCUL as of 1764288000 were 11633800 with a Short Ratio of 3.67, compared to 1761868800 on 13773939. Therefore, it implies a Short% of Shares Outstanding of 11633800 and a Short% of Float of 5.48.
Earnings Estimates
Current recommendations for the stock of the company come from 3.0 analysts. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.32 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$1.34 and -$1.49 for the fiscal current year, implying an average EPS of -$1.43. EPS for the following year is -$1.48, with 3.0 analysts recommending between -$1.3 and -$1.58.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $16.14M this quarter.It ranges from a high estimate of $28.4M to a low estimate of $11.6M. As of. The current estimate, Ocular Therapeutix Inc’s year-ago sales were $17.08MFor the next quarter, 12 analysts are estimating revenue of $14.01M. There is a high estimate of $16.6M for the next quarter, whereas the lowest estimate is $11.5M.
A total of 12 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.1M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.83M. In the same quarter a year ago, actual revenue was $63.72MBased on 12 analysts’ estimates, the company’s revenue will be $66.04M in the next fiscal year. The high estimate is $115.2M and the low estimate is $52.3M.
